Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

roche products (ireland) ltd - levodopa; benserazide - dispersible tablet - 100 mg/25 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

leyden delta bv - clozapine - orodispersible tablet - 100 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; clozapine

Iżrael - Ingliż - Ministry of Health

j-c health care ltd - etravirine - tablets - etravirine 100 mg - etravirine - etravirine - intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (nnrti) resistance. treatment history and when available resistance testing should guide the use of intelence. in patients who have experienced virological failure on an nnrti- and nucleoside or nucleotide reverse transcriptase inhibitor (n[t]rti) - containing regimen intelence is not recommended for use in combination with n(t)rtis only.

Kanada - Ingliż - Health Canada

hikma canada limited - hydrocortisone (hydrocortisone sodium succinate) - powder for solution - 100mg - hydrocortisone (hydrocortisone sodium succinate) 100mg - adrenals

Singapor - Ingliż - HSA (Health Sciences Authority)

mylan pharmaceuticals pte. ltd. - clozapine base - tablet, film coated - 100 mg - clozapine base 100 mg

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

napp pharmaceuticals ltd - canagliflozin hemihydrate - tablet - 100mg

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - hydrocortisone sodium succinate, quantity: 133.7 mg (equivalent: hydrocortisone, qty 100 mg) - injection, powder for - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate - when oral therapy is not feasible, and the strength, form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, [invented name] powder for injection is indicated for intravenous or intramuscular use in the following conditions: 1. endocrine disorders ? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplements may be necessary, particularly when synthetic analogues are used). ? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful ? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected ? congenital adrenal hyperplasia ? nonsuppurative thyroiditis ? hypercalcaemia associated with cancer. 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: ? post-traumatic osteoarthritis ? synovitis of osteoarthritis ? rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) ? acute and subacute bursitis ? epicondylitis ? acute nonspecific tenosynovitis ? acute gouty arthritis ? psoriatic arthritis ? ankylosing spondylitis. 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: ? systemic lupus erythematosus ? systemic dermatomyositis (polymyositis) ? acute rheumatic carditis. 4. dermatological diseases ? pemphigus ? severe erythema multiforme (stevens-johnson syndrome) ? exfoliative dermatitis ? bullous dermatitis herpetiformis ? severe seborrhoeic dermatitis ? severe psoriasis ? mycosis fungoides. 5. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: ? bronchial asthma ? drug hypersensitivity reactions ? contact dermatitis ? urticarial transfusion reactions ? atopic dermatitis ? serum sickness ? acute noninfectious laryngeal oedema (adrenaline is the drug of first choice). 6. ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye, such as: ? herpes zoster ophthalmicus ? iritis, iridocyclitis ? chorioretinitis ? diffuse posterior uveitis and choroiditis ? optic neuritis ? sympathetic ophthalmia ? anterior segment inflammation ? allergic conjunctivitis ? allergic corneal marginal ulcers ? keratitis. 7. gastrointestinal diseases to tide the patient over a critical period of the disease in: ? ulcerative colitis (systemic therapy) ? regional enteritis (systemic therapy). 8. respiratory diseases ? symptomatic sarcoidosis ? loeffler?s syndrome not manageable by other means ? berylliosis ? fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy ? aspiration pneumonitis. 9. haematological disorders ? acquired (autoimmune) haemolytic anaemia ? erythroblastopenia (rbc anaemia) ? idiopathic thrombocytopenic purpura in adults (iv only; im administration is contraindicated) ? secondary thrombocytopenia in adults ? congenital (erythroid) hypoplastic anaemia. 10. neoplastic diseases for palliative management of: ? leukaemias and lymphomas in adults ? acute leukaemia in childhood. 11. oedematous states ? to induce diuresis or remission of proteinuria in the nephrotic syndrome, without uraemia, of the idiopathic type or that due to lupus erythematosus. 12. miscellaneous ? tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurological or myocardial involvement.

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

rowex ltd - levonorgestrel; ethinylestradiol - coated tablet - 100 microg/20 microgram(s) - progestogens and estrogens, fixed combinations; levonorgestrel and ethinylestradiol

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

bayer limited - ethinylestradiol; levonorgestrel - tablet - 100/20 microgram(s) - progestogens and estrogens, fixed combinations; levonorgestrel and ethinylestradiol

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

consilient health limited - levonorgestrel; ethinylestradiol - film-coated tablet - 100/20 microgram(s) - progestogens and estrogens, fixed combinations; levonorgestrel and ethinylestradiol